Biography
Kelly Han is a member of the Firm's Mergers & Acquisitions Group. Her practice focuses on corporate matters with a particular emphasis on mergers and acquisitions and regulatory advisory matters.
Representative Legal Matters
- Advising a US-headquartered leading global chemical company in its advanced chemical product greenfield project in Shanghai with a total investment of up to approximately RMB 11.6 billion.
- Advising Hengten Networks on its acquisition of the entire issued share capital in Virtual Cinema Entertainment for a consideration of HKD 7.2 billion.
- Assisting a diversified international management and holding company and its affiliate on three parallel acquisition of state-owned equity interest in a major Chinese asset management company through public listing at two Chinese exchanges for considerations of over RMB 4.2 billion.
- Advising one of the largest USprivately-held conglomerate on its spinoff of apparel and advanced textile business in Asia Pacific, covering operations in nine jurisdictions (including mainland China, Hong Kong, Singapore, Japan, Korea, Taiwan, Australia, Thailand, India) and more than 20 entities.
- Advising a leading European fashion company in disposal of its equity interests in a winery in the PRC.
- Advising an Australia listed company in its investment in a buy-now-pay-after business in the telecommunication and finance industry in China.
- Advising a Fortune 500 hygiene products and services company for its acquisition of a PRC water treatment chemical producer and service provider at the consideration of RMB 1.1 billion and its formation of a joint venture in Hong Kong with the principal shareholders of the target.
- Advising a US listed engineering company for the establishment of a 50-50 joint venture with a state-owned and PRC listed offshore oil engineering company with a total project value of RMB 9.4 billion.
- Advising a leading US infusion therapy company on China aspects of its global acquisition of infusion system business for USD 900 million.
- Advising a UK-headquartered leading pharmaceutical company on buy-out of a minority shareholder in its China vaccine manufacturing joint venture and subsequent sale of the China subsidiary to offshore and online purchasers with a consideration of more than RMB 300 million.
Admission
People’s Republic of China (2021)
New York, USA (2017)
Education
Columbia University (LL.M. with the James Kent Scholar honor) (2016)
Fudan University (LL.B.) (2012)
Languages
English
Mandarin
Japanese